Plain-English translation of NCT06867536 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two treatments for people with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) that has a large tumor burden at the start. The study combines glofitamab, a newer immunotherapy medication that helps your immune system fight cancer cells, with radiation therapy. The researchers believe that combining these two treatments together may work better than the medication alone, especially for patients whose cancer has grown to a large size.
While glofitamab has been approved and shown promise in treating this type of lymphoma, patients who start with large tumors don't respond as well to the medication alone. Researchers believe that adding radiation therapy first may help prepare the immune system and improve how well the medication works, similar to results seen when radiation is combined with other immune therapies.
You likely qualify if…
You likely don't qualify if…
You would first receive radiation therapy delivered over 6 days (30 Gray total dose in focused beams to your tumor sites). About a week later, you would receive a preparatory infusion of obinutuzumab, followed by step-up doses of glofitamab starting at a low dose and increasing over two weeks, then continuing with standard doses every three weeks for up to 12 cycles. The study includes regular check-ins and imaging scans after 2 cycles and 4 cycles to see how well the treatment is working. The entire treatment period would span several months, with ongoing safety monitoring throughout.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China